Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer

Triple negative breast cancer (TNBC) is the most aggressive breast cancer accounting for around 15% of identified breast cancer cases. TNBC lacks human epidermal growth factor receptor 2 (HER2) amplification, is hormone independent estrogen (ER) and progesterone receptors (PR) negative, and is not r...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahman, Fatemah, Pittalà, Valeria, Haider, Mohamed, Greish, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234460/
https://www.ncbi.nlm.nih.gov/pubmed/34204015
http://dx.doi.org/10.3390/jpm11060559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234460/
https://www.ncbi.nlm.nih.gov/pubmed/34204015
http://dx.doi.org/10.3390/jpm11060559

Ejemplares similares